Today's Challenges. Tomorrow's Solutions.

Strategic Solutions for Physical Medicine & Rehabilitation That Turn Functional Recovery Into Enterprise Value

Physiatry earns across an unusually broad base — office E/M, electrodiagnostics, interventional injections, buy-and-bill botulinum toxin, and therapy ancillary — and every one of those lines is under separate payer pressure. Fulcrum Health Partners advises PM&R groups, spine and pain platforms, IRF-affiliated organizations, and PE-backed investors on commercial rate strategy, procedure and drug reimbursement, and post-acute value-based design — so the full revenue base is captured, contracted, and defended.

Model Your Reimbursement Opportunity → Speak with a PM&R Advisor

$2.7B

Reimbursement Opportunity Identified

12,500+

Payer Contracts Reviewed

States Served

350+

Client Engagements

The PM&R Reimbursement Landscape

The revenue base is broad. The pressure is on every line of it.

Physiatry is one of medicine's most diversified professional P&Ls — and that diversity is both the opportunity and the exposure. The margin lives in the procedures you capture, the drug you buy and bill, and the therapy you own.

A single physiatry practice can bill office and consultative E/M, electrodiagnostics (EMG/NCS), interventional spine and joint injections, spasticity management with botulinum toxin under buy-and-bill, and therapy (PT/OT) as an ancillary line — each governed by its own coverage rules, edits, and payer policy. Electrodiagnostic complexity is routinely under-documented, injection reimbursement swings on site-of-service, and buy-and-bill economics turn on acquisition cost versus allowable. The result is a revenue base that is rich in aggregate but leaks quietly, line by line.

Layered on top are prior-authorization regimes and therapy medical-necessity thresholds signaled by the KX modifier, workers'-compensation and out-of-network dynamics, prosthetics, orthotics, and DME, and — for IRF-affiliated groups — the discipline of the IRF PPS and the 60% Rule. As orthopedics and pain platforms consolidate and post-acute shifts toward functional-outcome and value-based models, the same physiatrist can be worth dramatically different amounts depending on how the full base is coded, contracted, and defended. That is precisely where Fulcrum works.

Illustrative composition. Replace with your confirmed figures before launch; reflects current CMS/MedPAC methodology and public payer data, 2024–2026.

Revenue Composition — Physiatry Professional Base (Illustrative)

Where PM&R margin is earned — and where it leaks

Office & consult E/M

Electrodiagnostics (EMG/NCS)

Interventional injections

Botulinum toxin (buy-and-bill)

Therapy (PT/OT) ancillary

The visit is one line of five. Fulcrum quantifies the full base — coded, contracted, and defended against leakage.

Distinct revenue lines in the physiatry professional base

60%

IRF PPS compliance threshold — the “60% Rule”

Modifier signaling medically necessary therapy above threshold

J-code

Botulinum toxin billed under buy-and-bill economics

Reimbursement Intelligence in Action

Your PM&R economics, by practice profile

Fulcrum turns your claims, charge, and contract data into executive dashboards. Select a profile to explore a sample payer-mix and revenue view spanning E/M and the procedure, drug, and therapy lines that define physiatry.

Independent Physiatry / Outpatient · Payer Mix & Revenue Live Sample

Payer Mix (by professional charges)

Net Revenue by Payer — E/M vs. Procedures, Drug & Therapy

E/M professional net paymentsProcedures, injections, botulinum & therapy

Illustrative sample dashboard. Fulcrum builds these from your practice-management, claims, charge, and contract data by CPT/HCPCS, payer, and contract.

Our PM&R Advisory Solutions

Advisory organized around the economics you manage

Not a service menu — the reimbursement problems that decide physiatry margin and enterprise value across every revenue line, and the strategy, analytics, and negotiation capabilities that resolve them.

01 The Challenge — You can't negotiate what you haven't benchmarked

Contract Assessment & Reimbursement Benchmarking

We digitize and normalize every payer contract and fee schedule, then benchmark your PM&R reimbursement — E/M, electrodiagnostics, injections, botulinum toxin, and therapy — against Medicare and against market using proprietary intelligence, quantifying exactly where you sit and what the opportunity is worth line by line.

Contract digitization

Fee schedule normalization

% of Medicare benchmarking

Electrodiagnostic & injection rate analysis

Buy-and-bill (ASP) benchmarking

Therapy & DME fee review

Site-of-service differential analysis

Revenue opportunity quantification

Contract performance scoring

02 The Challenge — Little leverage one contract at a time

Managed Care Negotiations & Strategy

We build the positioning, data, and negotiation strategy to improve commercial rates across E/M, procedures, drug, and therapy — and to secure workers'-comp and out-of-network terms that reflect the value physiatry actually delivers.

Commercial rate improvement

Contract renewals & redlining

MA & Medicaid managed care

Workers'-comp & OON strategy

Escalation & executive strategy

Network participation strategy

03 The Challenge — Decisions made without modeling the downside

Contract Modeling & Analytics

CPT- and HCPCS-level modeling that turns claims and contracts into scenario analysis, revenue forecasts, and site-of-service and buy-and-bill margin comparisons your executives can act on.

CPT/HCPCS-level modeling

Scenario & what-if analysis

Site-of-service margin modeling

Buy-and-bill drug margin analysis

Payer mix & revenue forecasting

Executive Power BI dashboards

04 The Challenge — Negotiating blind to what competitors are paid

Payer Transparency & Market Rate Intelligence

Federal Transparency in Coverage data has transformed the negotiating table. We mine machine-readable rate files to show what competing physiatry, spine, and pain groups are actually paid for the same codes — and arm your team with it.

Transparency in Coverage analysis

Competitor rate benchmarking

Procedure & drug rate positioning

Negotiation preparation

Peer comparison

Commercial opportunity sizing

05 The Challenge — Effort spread evenly across unequal payers

Covered Lives & Market Intelligence

We map covered lives, payer penetration, referral sources, and workers'-comp volume across your market so you prioritize the negotiations and service-line investments that move the most margin.

Covered-lives analysis

Payer penetration & market share

Referral & post-acute dynamics

Workers'-comp volume mapping

Employer & population trends

Commercial opportunity identification

06 The Challenge — Contract terms that aren't honored

Payer / Provider Disputes & Enforcement

When payers deny electrodiagnostics, bundle injections, challenge medical necessity, or restrict buy-and-bill, we lead the interpretation, escalation, and enforcement — turning contractual entitlement into collected revenue.

Contract interpretation

Payment & claims disputes

Bundling & medical-necessity challenges

Escalation support

Executive negotiation

Contract enforcement

07 The Challenge — Earned revenue that never arrives — or is clawed back

Underpayment / Overpayment Recovery & Revenue Integrity

Our analytics compare contracts, fee schedules, ASP-based allowables, and EOB/remittance data to detect variances in both directions — quantifying recoverable underpayments, defending against improper takebacks, and fixing the root cause so leakage stops.

Contract compliance auditing

Underpayment & variance detection

Overpayment / takeback defense

Automated EOB/remit analytics

Recovery & appeals strategy

Revenue integrity programs

The Forces Reshaping PM&R Economics

The strategic questions every physiatry leader now faces

Beyond the fee schedule, these are the dynamics that decide PM&R margin across every revenue line — and where Fulcrum builds the strategy.

Site-of-Service & Injection Economics

How injection and procedure margin swings between office, ASC, and hospital outpatient settings — and how to contract and steer for the setting that protects reimbursement.

Prior Authorization & Therapy Medical Necessity

Managing prior-authorization burden and therapy thresholds signaled by the KX modifier, where documentation gaps convert directly into denials and takebacks.

Buy-and-Bill Botulinum-Toxin Margin

Protecting spasticity-management economics where acquisition cost, ASP-based allowables, and payer utilization policy determine whether the drug earns or erodes margin.

IRF PPS & the 60% Rule

Navigating inpatient rehabilitation facility medical direction, case-mix, and the compliance threshold that governs qualifying admissions and facility economics.

Consolidation with Ortho & Pain Platforms

Competing with — and evaluating alignment against — orthopedic, spine, and pain platforms and PE-backed rehabilitation groups now consolidating physiatry.

Value-Based & Functional-Outcome Models

Positioning for post-acute bundles and functional-outcome arrangements that reward recovery trajectory rather than procedure volume alone.

PM&R Reimbursement Calculator

See what a fully captured, well-contracted base is worth

Model the annual uplift from three physiatry levers: capturing under-billed electrodiagnostic and injection procedures, adding therapy (PT/OT) ancillary contribution, and moving commercial rates toward optimized levels expressed as a percentage of Medicare.

Your inputs

Enter approximate figures — nothing is stored or transmitted.

Annual commercial professional revenue

Electrodiagnostic & injection capture uplift (% of base)

Therapy (PT/OT) ancillary contribution (% of base)

Current commercial rate (% of Medicare)

Optimized commercial rate (% of Medicare) — 130%

Estimated annual reimbursement uplift

Adjust the inputs to model your opportunity.

Per $1M of commercial revenue

3-year cumulative

Directional estimate for discussion only. Combines procedure/injection capture, therapy ancillary contribution, and commercial rate improvement; buy-and-bill drug margin, workers'-comp, and IRF economics are modeled separately. A Fulcrum analysis models your actual contracts, charges, and payer mix.

Client Outcomes

How Fulcrum helps — and what it's worth

Anonymized outcomes from Fulcrum engagements with physical medicine and rehabilitation groups and platforms.

Independent Physiatry Group

21%

commercial rate improvement

Situation: a physiatry group was paid well below market on electrodiagnostics and injections and had never benchmarked its contracts. Result: we repositioned the group on procedure-level data and renegotiated its top commercial payers, lifting blended commercial reimbursement without adding a single encounter.

Spine & Rehabilitation Platform

$3.8M

recovered procedure & drug revenue

Situation: bundled injection denials and buy-and-bill botulinum underpayments were quietly eroding margin across sites. Result: automated remit analytics isolated the variances, recovered the shortfall, and remediated the root-cause edits so the leakage stopped.

PE-Backed Rehab & Pain Group

8 pts

margin from contract harmonization

Situation: a multi-state platform carried a patchwork of legacy physiatry, therapy, and DME contracts ahead of a recapitalization. Result: we harmonized terms, aligned site-of-service strategy, and recovered systematic underpayments — lifting EBITDA before diligence.

Why PM&R Leaders Choose Fulcrum

The advisor that speaks physiatry's economic language

Independent by design and fluent in the full physiatry base — E/M, electrodiagnostics, injections, buy-and-bill botulinum toxin, therapy, and post-acute — delivered by the people who do the work.

Independent Advisor

No networks, no downstream fees — only your economics.

Full-Base PM&R Fluency

Fluent across E/M, electrodiagnostics, injections, drug, and therapy.

Commercial Rate Benchmarking

Market and transparency data behind every ask.

CPT/HCPCS & Buy-and-Bill Analytics

Modeling down to the code, the drug, and the site of service.

National Payer Experience

Insight into payer policy and edits in every market.

IRF, Therapy & DME Insight

Command of the 60% Rule, KX thresholds, and ancillary lines.

Negotiation Leadership

Senior advisors at the table, not junior staff.

Data-Driven Support

Dashboards and intelligence that clarify the path.

Fulcrum Intelligence

Physical medicine & rehabilitation insights & analysis

Executive briefings on the forces moving physiatry economics — electrodiagnostic and injection reimbursement, buy-and-bill drug margin, therapy thresholds, IRF policy, and post-acute value.

Site-of-Service & the Injection Margin Question → Defending Buy-and-Bill Botulinum-Toxin Economics →

Explore PM&R Insights →